Glenmede Trust’s Kymera Therapeutics KYMR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$240K Sell
4,241
-3,153
-43% -$361K ﹤0.01% 1190
2026
Q2
$848K Buy
7,394
+615
+9% +$52.8K ﹤0.01% 829
2026
Q1
$565K Buy
6,779
+235
+4% +$18.6K ﹤0.01% 921
2025
Q4
$509K Buy
+6,544
New +$442K ﹤0.01% 938
2021
Q3
– Sell
-5,000
Closed -$242K – 1316
2021
Q2
$242K Buy
+5,000
New +$217K ﹤0.01% 1090

Other funds holding KYMR

Glenmede Trust's KYMR Position: Q3 2026 in Review

Glenmede Trust reduced its Kymera Therapeutics (KYMR) stake by 43% in Q3 2026, selling an estimated $361K and leaving 4,241 shares worth $240K. The position accounts for ﹤0.01% of the portfolio, ranked #1190.

Glenmede Trust first reported a position in KYMR in Q2 2021 and has held it in 5 quarters since. The position peaked at $848K in Q2 2026. 301 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.

  • Glenmede Trust held 4,241 shares of Kymera Therapeutics worth $240K as of Q3 2026.
  • Glenmede Trust sold 3,153 Kymera Therapeutics shares in Q3 2026, an estimated $361K.
  • Kymera Therapeutics made up ﹤0.01% of Glenmede Trust's portfolio in Q3 2026, its #1190 holding.
  • Glenmede Trust first reported a position in Kymera Therapeutics in Q2 2021 and has held it in 5 quarters since.
  • Glenmede Trust's Kymera Therapeutics position peaked at $848K in Q2 2026.
  • 301 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.

Based on Glenmede Trust's 13F filing for Q3 2026, filed 16 Nov 2026.